Inari Medical, Inc.
NARI · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.77 | -0.81 | -0.07 | 0.85 |
| FCF Yield | -0.04% | 0.24% | -0.52% | 0.26% |
| EV / EBITDA | -332.68 | -173.48 | -236.84 | -3,943.82 |
| Quality | ||||
| ROIC | -3.57% | -4.26% | -4.48% | -0.39% |
| Gross Margin | 87.06% | 83.86% | 86.81% | 86.27% |
| Cash Conversion Ratio | -0.15 | -0.37 | 0.51 | -2.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.98% | 17.72% | 19.34% | 21.24% |
| Free Cash Flow Growth | -114.35% | 148.83% | -244.27% | -31.33% |
| Safety | ||||
| Net Debt / EBITDA | 1.17 | 2.23 | 3.09 | 7.56 |
| Interest Coverage | -173.95 | -203.64 | -220.22 | -23.17 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.48 | 0.42 | 0.42 |
| Cash Conversion Cycle | 229.50 | 176.48 | 204.82 | 208.15 |